Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2016-002424-86 | EudraCT Number | ||
| 54135419TRD1019 | Other Identifier | Janssen Research & Development, LLC |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary purpose of this study is to evaluate the effect of a single 84-milligram (mg) dose of intranasal esketamine compared to placebo, on next day driving performance and repeated administration of 84 mg intranasal esketamine on same-day driving performance as assessed by the mean difference of standard deviation of lateral position (SDLP) from an on-road driving test.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Part A: Sequence ABC (Placebo+Alcohol+Esketamine) | Experimental | Participants will receive intranasal placebo on Day 1 and oral placebo on Day 2 [Treatment A] in Period 1, then intranasal placebo on Day 1 and Oral alcohol on Day 2 [Treatment B] in Period 2, followed by intranasal esketamine on Day 1 and oral placebo on Day 2 [Treatment C] in Period 3. |
|
| Part A: Sequence BCA (Placebo+Alcohol+Esketamine) | Experimental | Participants will receive Treatment B in Period 1, then Treatment C in Period 2, followed by Treatment A in Period 3. |
|
| Part A: Sequence CAB (Placebo+Alcohol+Esketamine) | Experimental | Participants will receive Treatment C in Period 1, then Treatment A in Period 2, followed by Treatment B in Period 3. |
|
| Part A: Sequence CBA (Placebo+Alcohol+Esketamine) | Experimental | Participants will receive Treatment C in Period 1, then Treatment B in Period 2, followed by Treatment A in Period 3. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placebo (Intranasal) | Drug | Participants will receive intranasal placebo in Part A (as per the treatment sequence in period 1,2 and 3) and Part B. |
|
| Measure | Description | Time Frame |
|---|---|---|
| The Effect of a Single 84-Milligram (mg) Dose of Intranasal Esketamine Compared to Placebo, on Next day Driving Performance and Repeated Administration of 84 mg Intranasal Esketamine on Same-day Driving Performance | Driving performance will be assessed by the mean difference of standard deviation of lateral position (SDLP) from an on-road driving test. | Part A: Day 2 |
| The Effect of a Single 84-mg Dose of Intranasal Esketamine Compared to Placebo, on Next day Driving Performance and Repeated Administration of 84 mg Intranasal Esketamine on Same-day Driving Performance | Driving performance will be assessed by the mean difference of standard deviation of lateral position (SDLP) from an on-road driving test. | Part B: Day 1 |
| The Effect of a Single 84-mg Dose of Intranasal Esketamine Compared to Placebo, on Next day Driving Performance and Repeated Administration of 84 mg Intranasal Esketamine on Same-day Driving Performance | Driving performance will be assessed by the mean difference of standard deviation of lateral position (SDLP) from an on-road driving test. | Part B: Day 11 |
| The Effect of a Single 84-mg Dose of Intranasal Esketamine Compared to Placebo, on Next day Driving Performance and Repeated Administration of 84 mg Intranasal Esketamine on Same-day Driving Performance | Driving performance will be assessed by the mean difference of standard deviation of lateral position (SDLP) from an on-road driving test. | Part B: Day 18 |
| The Effect of a Single 84-mg Dose of Intranasal Esketamine Compared to Placebo, on Next day Driving Performance and Repeated Administration of 84 mg Intranasal Esketamine on Same-day Driving Performance | Driving performance will be assessed by the mean difference of standard deviation of lateral position (SDLP) from an on-road driving test. |
| Measure | Description | Time Frame |
|---|---|---|
| Effect on Subjective Driving Ability Scale | Immediately after each driving test, subjects will indicate the perceived quality of their driving performance on a visual analog scale from 0 ('I drove exceptionally poorly') to 20 ('I drove exceptionally well') around a midpoint of 'I drove normally'. | Part A: Day 2; Part B: Day 1, 11, 18 and 25 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Janssen Research & Development, LLC Clinical Trial | Janssen Research & Development, LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Leiden | Netherlands |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35212235 | Derived | Dijkstra FM, van de Loo AJ, Abdulahad S, Bosma ER, Hartog M, Huls H, Kuijper DC, de Vries E, Solanki B, Singh J, Aluisio L, Zannikos P, Stuurman FE, Jacobs GE, Verster JC. The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder. J Psychopharmacol. 2022 May;36(5):614-625. doi: 10.1177/02698811221078764. Epub 2022 Feb 25. |
| Label | URL |
|---|---|
| A Placebo- and Active-Controlled Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Subjects With Major Depressive Disorder (DriveSaFe2) | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Part A: Sequence ACB (Placebo+Alcohol+Esketamine) | Experimental | Participants will receive Treatment A in Period 1, then Treatment C in Period 2, followed by Treatment B in Period 3. |
|
| Part A: Sequence BAC (Placebo+Alcohol+Esketamine) | Experimental | Participants will receive Treatment B in Period 1, then Treatment A in Period 2, followed by Treatment C in Period 3. |
|
| Part B: Placebo+Esketamine | Experimental | Participants will receive intranasal placebo on Day 1, followed by intranasal esketamine on Days 4, 8, 11, 15, 18, 22 and 25. |
|
| Esketamine | Drug | Participants will receive intranasal esketamine in Part A (as per the treatment sequence in period 1,2 and 3) and Part B. |
|
| Alcohol | Other | Participants will receive oral alcohol in Part A (as per the treatment sequence in period 1,2 and 3). |
|
| Placebo (Oral) | Drug | Participants will receive oral placebo in Part A (as per the treatment sequence in period 1,2 and 3). |
|
| Part B: Day 25 |
| Karolinska Sleepiness Scale (KSS) Score |
KSS is a participant reported assessment used to rate sleepiness on a scale of 1 to 9, ranging from 'extremely alert' (1) to 'very sleepy, great effort to keep awake, fighting sleep (9). |
| Part A: Day 2; Part B: Day 1, 11, 18 and 25 |
| Efficacy Measured by the Montgomery Asberg Depression Rating Scale (MADRS) | MADRS consists of 10 items covering all the important complaints which Participant with depression have (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts). Item is scored from 0 (normal) to 6 (severe). Total score (0 to 60) is calculated by adding the scores of all 10 items. A higher score represents a more severe condition. Negative Change in Score Indicates Improvement. | Baseline; Part A: Predose, Day 2; Part B: Predose, Days 1, 11, 18, and 25; End of study (up to Day 98) |
| Effects on Suicidal Ideation/Behavior Measured by the Columbia Suicide Severity Rating Scale (C-SSRS) | C-SSRS is a clinician rated assessment of suicidal behavior and / or intent. Scale consists of 28 items in 4 sections: suicide behavior, actual attempts, suicidal ideation, and intensity of ideation. Suicidal ideation consists of 5 'yes/no' items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent. Only items with yes responses are listed. Worsening of suicidal ideation was an increase in severity of suicidal ideation from baseline. | Baseline; Part A: Predose, Day 2; Part B: Predose, Days 1, 11, 18, and 25; End of study (up to Day 98) |
| Effects on Dissociative Symptoms Using the Clinician-Administered Dissociative State Scale (CADSS) | The CADSS is an instrument for the measurement of present-state dissociative symptoms. The CADSS comprises 23 subjective items, divided into 3 components: Depersonalization, Derealization and Amnesia. Participant's responses are coded on a 5-point scale (0 = "Not at all" through to 4 = "Extremely"). | Baseline; Part A: Predose, Day 1; Part B: Predose, Days 1, 11, 18, and 25 |
| Potential Relationship Between Changes in SDLP and the Plasma Concentration of Esketamine and Noresketamine | Potential relationship will be assessed using visual displays of data. The relationship between the standard deviation of lateral position (SDLP) and the concentration of esketamine and noresketamine in plasma will be evaluated. | Part A: 1 hour postdose (Day 1); Part B: 1 hour postdose (Day 11, 18 and 25) |
| Effect on Subjective Mental Effort Scale | The level of mental effort the participant had to invest in performing the driving test will be assessed on a 15 centimeter (cm) visual analogue scale with markings ranging from 'absolutely no effort' to over 'extreme effort. | Part A: Day 2; Part B: Day 1, 11, 18 and 25 |
| Potential Relationship Between Changes in Mean Lateral Position (MLP) and the Plasma Concentration of Esketamine and Noresketamine | Potential relationship will be assessed using visual displays of data. The relationship between the MLP and the concentration of esketamine and noresketamine in plasma will be evaluated. The MLP will be measured from a validated on-road driving test in a 100 kilometer (km) highway-driving lane. | Part A: 1 hour postdose (Day 1); Part B: 1 hour postdose (Day 11, 18 and 25) |
| Potential Relationship Between Changes in Mean Speed and the Plasma Concentration of Esketamine and Noresketamine | Potential relationship will be assessed using visual displays of data. The relationship between the mean speed (MS) and the concentration of esketamine and noresketamine in plasma will be evaluated. The MS will be measured from a validated on-road driving test in a 100 km highway-driving lane. | Part A: 1 hour postdose (Day 1); Part B: 1 hour postdose (Day 11, 18 and 25) |
| ID | Term |
|---|---|
| D003865 | Depressive Disorder, Major |
| ID | Term |
|---|---|
| D003866 | Depressive Disorder |
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C000629870 | Esketamine |
| D000431 | Ethanol |
| ID | Term |
|---|---|
| D000438 | Alcohols |
| D009930 | Organic Chemicals |
Not provided
Not provided